Article Text
Abstract
Predictive genetic testing for a neurodegenerative condition in one individual in a family may have implications for other family members, in that it can reveal their genetic status. Herein a complex clinical case is explored where the testing wish of one family member was in direct conflict to that of another. The son of a person at 50% risk of an autosomal dominant neurodegenerative condition requested testing to reveal his genetic status. The main reason for the request was if he had the familial mutation, he and his partner planned to utilise preimplantation genetic diagnosis to prevent his offspring having the condition. His at-risk parent was clear that if they found out they had the mutation, they would commit suicide. We assess the potential benefits and harms from acceding to or denying such a request and present an approach to balancing competing rights of individuals within families at risk of late-onset genetic conditions, where family members have irreconcilable differences with respect to predictive testing. We argue that while it may not be possible to completely avoid harm in these situations, it is important to consider the magnitude of risks, and make every effort to limit the potential for adverse outcomes.
- Genetic Counselling/Prenatal Diagnosis
- Genethics
- Genetic Screening/Testing
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Genetic testing and reproductive choice in neurological disorders
- The right not to know and preimplantation genetic diagnosis for Huntington’s disease
- Paradox of a better test for Huntington's disease
- Clinical applications of preimplantation genetic testing
- Huntington’s disease
- Understanding of and attitudes to genetic testing for inherited retinal disease: a patient perspective
- Preimplantation genetic diagnosis in clinical practice
- Prenatal testing for Huntington's disease: experience within the UK 1994-1998
- Primary prevention of neurological illness early in life
- Britain’s new preimplantation tissue typing policy: an ethical defence